image credit- freepik
Japanese pharma firm Takeda and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM and the Coordinating Ministry for Economic Affairs) have announced a groundbreaking collaboration aimed at strengthening Indonesia’s plasma ecosystem and supporting more equitable access to lifesaving plasma-derived medicinal products (PDMPs) in Indonesia and around the world.
Marked by a fractionation license granted to Takeda by the Ministry of Health (MoH), the collaboration is a major milestone in advancing Indonesia’s health resilience and biopharmaceutical manufacturing capabilities.
The vision for this multi-year initiative, the first of its kind in the Association of Southeast Asian Nations (ASEAN) region, is focused on the sustainable collection of high-quality plasma and manufacturing of PDMPs at scale.
As part of the initial phase of the project, Takeda will invest up to $30 million in a two-year pilot program to establish plasma donation centres in Indonesia, enabling Takeda and the MoH to evaluate feasibility and refine operational models ahead of a potential scale-up into a national network. These centres will leverage Takeda’s global plasma donation expertise and adhere to stringent international quality and regulatory standards.
The initiative is expected to create new employment opportunities, including highly skilled positions for healthcare professionals and laboratory technicians, while supporting workforce training and the transfer of international standard practices.
